s-5682 and Pain

s-5682 has been researched along with Pain* in 2 studies

Other Studies

2 other study(ies) available for s-5682 and Pain

Article	Year
Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1. Advances in therapy, 2018, Volume: 35, Issue:7 Sclerotherapy is a common technique for the removal of intradermal veins. This study examined the rationale for prescribing micronized purified flavonoid fraction (MPFF) in clinical, etiological, anatomic, pathophysiologic (CEAP) class C1 patients with dilated intradermal veins scheduled for sclerotherapy.. In a national, multicenter, observational program, physicians recruited CEAP C1s patients scheduled for sclerotherapy. The decision to prescribe adjuvant MPFF (1000 mg/day for 6 weeks beginning 2 weeks before sclerotherapy) was made according to usual practice. Disease severity and treatment outcomes were assessed at baseline and 4 weeks post-sclerotherapy using a visual analog scale (VAS) as well as quality-of-life (CIVIQ-14) and patient satisfaction (Darvall) questionnaires.. A total of 70 physicians recruited 1150 patients: 1071 (93%) women, 79 (7%) men. Mean age (± SD) was 40.7 ± 10.7 years (range 18-74) and mean body mass index was 23.6 ± 3.3 kg/m. Resolution of venous symptoms post-sclerotherapy was greater in patients treated with MPFF compared with those undergoing sclerotherapy alone, supporting the rationale for use of MPFF in patients undergoing sclerotherapy.. Servier. Topics: Administration, Oral; Adult; Chronic Disease; Diosmin; Drug Combinations; Edema; Female; Flavonoids; Hesperidin; Humans; Male; Middle Aged; Pain; Pre-Exposure Prophylaxis; Quality of Life; Sclerotherapy; Surveys and Questionnaires; Telangiectasis; Treatment Outcome	2018
At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life. Angiology, 1994, Volume: 45, Issue:6 Pt 2 A research program has been developed to define an evaluation tool capable of assessing the impact of venous insufficiency and its treatments on the patient's everyday life. The methodology is described in the first part of this paper, followed by the results of the first phase of the research program, based on two surveys: a "qualitative" survey in a population of severely affected patients and a "quantitative" survey in a population of 150 patients. Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Diosmin; Drug Combinations; Female; Flavonoids; Hesperidin; Humans; Male; Middle Aged; Pain; Quality of Life; Varicose Veins; Venous Insufficiency	1994

Article

Year

Administration of Micronized Purified Flavonoid Fraction During Sclerotherapy of Reticular Veins and Telangiectasias: Results of the National, Multicenter, Observational Program VEIN ACT PROLONGED-C1.

Advances in therapy, 2018, Volume: 35, Issue:7

Sclerotherapy is a common technique for the removal of intradermal veins. This study examined the rationale for prescribing micronized purified flavonoid fraction (MPFF) in clinical, etiological, anatomic, pathophysiologic (CEAP) class C1 patients with dilated intradermal veins scheduled for sclerotherapy.. In a national, multicenter, observational program, physicians recruited CEAP C1s patients scheduled for sclerotherapy. The decision to prescribe adjuvant MPFF (1000 mg/day for 6 weeks beginning 2 weeks before sclerotherapy) was made according to usual practice. Disease severity and treatment outcomes were assessed at baseline and 4 weeks post-sclerotherapy using a visual analog scale (VAS) as well as quality-of-life (CIVIQ-14) and patient satisfaction (Darvall) questionnaires.. A total of 70 physicians recruited 1150 patients: 1071 (93%) women, 79 (7%) men. Mean age (± SD) was 40.7 ± 10.7 years (range 18-74) and mean body mass index was 23.6 ± 3.3 kg/m. Resolution of venous symptoms post-sclerotherapy was greater in patients treated with MPFF compared with those undergoing sclerotherapy alone, supporting the rationale for use of MPFF in patients undergoing sclerotherapy.. Servier.

Topics: Administration, Oral; Adult; Chronic Disease; Diosmin; Drug Combinations; Edema; Female; Flavonoids; Hesperidin; Humans; Male; Middle Aged; Pain; Pre-Exposure Prophylaxis; Quality of Life; Sclerotherapy; Surveys and Questionnaires; Telangiectasis; Treatment Outcome

2018

At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life.

Angiology, 1994, Volume: 45, Issue:6 Pt 2

A research program has been developed to define an evaluation tool capable of assessing the impact of venous insufficiency and its treatments on the patient's everyday life. The methodology is described in the first part of this paper, followed by the results of the first phase of the research program, based on two surveys: a "qualitative" survey in a population of severely affected patients and a "quantitative" survey in a population of 150 patients.

Topics: Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Diosmin; Drug Combinations; Female; Flavonoids; Hesperidin; Humans; Male; Middle Aged; Pain; Quality of Life; Varicose Veins; Venous Insufficiency

1994